Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Darvadstrocel in Complex Perianal Fistula in Crohn's Disease (ADMIRE II Follow-up)
2019-000333-39Phase 4Completed
- Sponsor
- Takeda
- Start
- Sep 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of darvadstrocel in Crohn's disease and anal fistula, sponsored by Takeda. Primary endpoints: Long-term safety - adverse events, Long-term safety - serious adverse events and 1 more. Started Sep 2019; status: completed.
02
Drugs
darvadstrocel
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on 2019-000333-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000333-39.